Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

ELMI - Prospective, Randomized, Controlled, Parallel-arm Study to Assess the Effects of the Combined Therapy of Empagliflozin and Linagliptin Compared to Metformin and Insulin Glargine on Renal and Vascular Changes in Type 2 Diabetes

NCT02752113 is registered in ClinicalTrials.gov with Institut für Pharmakologie und Präventive Medizin as lead sponsor.

NCT NCT02752113
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02752113 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
ELMI - Prospective, Randomized, Controlled, Parallel-arm Study to Assess the Effects of the Combined Therapy of Empagliflozin and Linagliptin Compared to Metformin and Insulin Glargine on Renal and Vascular Changes in Type 2 Diabetes
Lead sponsor
Institut für Pharmakologie und Präventive Medizin
Phase
Phase 3
Overall status
Completed
Start date
April 30, 2016
Completion date
May 31, 2019
Enrollment
101 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

diabetes mellitus type 2